Literature DB >> 9203650

Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease.

M Shinkai1, S A Bozzette, W Powderly, P Frame, S A Spector.   

Abstract

Urine and blood leukocyte cultures and qualitative plasma polymerase chain reaction (PCR) and quantitative competitive (QC) PCR were evaluated for their ability to identify AIDS patients at risk for human cytomegalovirus (HCMV) disease. AIDS patients were followed with urine and blood specimens every 3 months. During a mean follow-up of 12 months, 26 (28%) developed HCMV disease. The sensitivity, specificity, positive predictive value, and negative predictive value for urine culture were 85%, 29%, 31%, and 83%; for leukocyte culture were 38%, 74%, 69%, and 81%; for qualitative plasma PCR were 89%, 75%, 58%, and 94%; for QC-PCR (>1000 copies/microL) were 35%, 100%, 100%, and 80%; and for QC-PCR (>100 copies/microL) were 73%, 90%, 73%, and 90%, respectively. Of 41 patients identified by qualitative PCR to have HCMV DNA in plasma, the 24 who developed HCMV disease had 1510 +/- 448 (mean +/- SE) peak copies of HCMV DNA/microL by QC-PCR, versus 161 +/- 52 for the 17 patients who did not develop disease (P = .0007). Thus, plasma PCR is superior to culture for identification of AIDS patients at risk for HCMV disease, and quantitation of plasma DNA further identifies high-risk persons.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203650     DOI: 10.1093/infdis/175.2.302

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

1.  Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma.

Authors:  A M Caliendo; R Schuurman; B Yen-Lieberman; S A Spector; J Andersen; R Manjiry; C Crumpacker; N S Lurain; A Erice
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

2.  A highly sensitive assay for detection and quantitation of human cytomegalovirus DNA in serum and plasma by PCR and electrochemiluminescence.

Authors:  R Boom; C Sol; J Weel; Y Gerrits; M de Boer; P Wertheim-van Dillen
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

3.  Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patients.

Authors:  B S Blank; P L Meenhorst; J W Mulder; G J Weverling; H Putter; W Pauw; W C van Dijk; P Smits; S Lie-A-Ling; P Reiss; J M Lange
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

4.  Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis.

Authors:  Roland R Regoes; E Frances Bowen; Alethea V Cope; Dehila Gor; Aycan F Hassan-Walker; H Grant Prentice; Margaret A Johnson; Paul Sweny; Andrew K Burroughs; Paul D Griffiths; Sebastian Bonhoeffer; Vincent C Emery
Journal:  Proc Biol Sci       Date:  2006-08-07       Impact factor: 5.349

5.  Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan.

Authors:  Masaaki Minami; Michio Ohta; Teruko Ohkura; Takafumi Ando; Naoki Ohmiya; Yasumasa Niwa; Hidemi Goto
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

6.  Evaluation of the AMPLICOR cytomegalovirus test with specimens from human immunodeficiency virus-infected subjects.

Authors:  G Boivin; J Handfield; E Toma; G Murray; R Lalonde; V J Tevere; R Sun; M G Bergeron
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

7.  Detection of DNA of lymphotropic herpesviruses in plasma of human immunodeficiency virus-infected patients: frequency and clinical significance.

Authors:  Francesco Broccolo; Simona Bossolasco; Anna M Careddu; Giuseppe Tambussi; Adriano Lazzarin; Paola Cinque
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

8.  Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease.

Authors:  F D Verbraak; R Boom; P M Wertheim-van Dillen; G J van den Horn; A Kijlstra; M D de Smet
Journal:  Br J Ophthalmol       Date:  1999-10       Impact factor: 4.638

9.  Screening for CMV retinitis using chromatic discrimination thresholds and achromatic contrast sensitivity.

Authors:  R S Newsom; G L Ong; T L Jackson; I Coldrick; L G Ripley; M Fisher; A G Casswell
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

10.  Evaluation of the murex hybrid capture cytomegalovirus DNA assay versus plasma PCR and shell vial assay for diagnosis of human cytomegalovirus viremia in immunocompromised patients.

Authors:  W Y Barrett-Muir; C Aitken; K Templeton; M Raftery; S M Kelsey; J Breuer
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.